Avidity Biosciences (RNA) FCF Margin: 2019-2025
Historic FCF Margin for Avidity Biosciences (RNA) over the last 6 years, with Sep 2025 value amounting to -1,257.60%.
- Avidity Biosciences' FCF Margin rose 162421.00% to -1,257.60% in Q3 2025 from the same period last year, while for Sep 2025 it was -2,838.14%, marking a year-over-year decrease of 97483.00%. This contributed to the annual value of -2,825.88% for FY2024, which is 153621.00% down from last year.
- According to the latest figures from Q3 2025, Avidity Biosciences' FCF Margin is -1,257.60%, which was up 76.17% from -5,277.07% recorded in Q2 2025.
- In the past 5 years, Avidity Biosciences' FCF Margin ranged from a high of 713.09% in Q4 2023 and a low of -8,174.32% during Q1 2025.
- In the last 3 years, Avidity Biosciences' FCF Margin had a median value of -2,274.38% in 2023 and averaged -2,852.34%.
- Per our database at Business Quant, Avidity Biosciences' FCF Margin spiked by 215,906bps in 2023 and then tumbled by 616,204bps in 2025.
- Quarterly analysis of 5 years shows Avidity Biosciences' FCF Margin stood at -1,507.67% in 2021, then surged by 6,169bps to -1,445.97% in 2022, then soared by 215,906bps to 713.09% in 2023, then crashed by 420,407bps to -3,490.99% in 2024, then skyrocketed by 162,421bps to -1,257.60% in 2025.
- Its last three reported values are -1,257.60% in Q3 2025, -5,277.07% for Q2 2025, and -8,174.32% during Q1 2025.